PLSE Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of -22540.7% compared to Pulse Biosciences, Inc.'s net margin of 4.09%. Pulse Biosciences, Inc.'s return on equity of -73.32% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

Pulse Biosciences, Inc. has a consensus price target of $26.00, signalling upside risk potential of 3.67%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.50 which suggests that it could grow by 22.28%. Given that Edwards Lifesciences Corp. has higher upside potential than Pulse Biosciences, Inc., analysts believe Edwards Lifesciences Corp. is more attractive than Pulse Biosciences, Inc..

Pulse Biosciences, Inc. has a beta of 1.776, which suggesting that the stock is 77.577% more volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.133%.

Pulse Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Pulse Biosciences, Inc. quarterly revenues are $86K, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Pulse Biosciences, Inc.'s net income of -$19.4M is lower than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, Pulse Biosciences, Inc.'s price-to-earnings ratio is -- while Edwards Lifesciences Corp.'s PE ratio is 42.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences, Inc. is 19,236.00x versus 7.62x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -22540.7% compared to Pulse Biosciences, Inc.'s net margin of -1118.87%. Pulse Biosciences, Inc.'s return on equity of -73.32% beat Nutriband, Inc.'s return on equity of -164.64%.

Pulse Biosciences, Inc. has a consensus price target of $26.00, signalling upside risk potential of 3.67%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 257.57%. Given that Nutriband, Inc. has higher upside potential than Pulse Biosciences, Inc., analysts believe Nutriband, Inc. is more attractive than Pulse Biosciences, Inc..

Pulse Biosciences, Inc. has a beta of 1.776, which suggesting that the stock is 77.577% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.

Pulse Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Pulse Biosciences, Inc. quarterly revenues are $86K, which are smaller than Nutriband, Inc. quarterly revenues of $346.1K. Pulse Biosciences, Inc.'s net income of -$19.4M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Pulse Biosciences, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences, Inc. is 19,236.00x versus 20.93x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PetVivo Holdings, Inc. has a net margin of -22540.7% compared to Pulse Biosciences, Inc.'s net margin of -765.99%. Pulse Biosciences, Inc.'s return on equity of -73.32% beat PetVivo Holdings, Inc.'s return on equity of -335.08%.

Pulse Biosciences, Inc. has a consensus price target of $26.00, signalling upside risk potential of 3.67%. On the other hand PetVivo Holdings, Inc. has an analysts' consensus of -- which suggests that it could grow by 635.19%. Given that PetVivo Holdings, Inc. has higher upside potential than Pulse Biosciences, Inc., analysts believe PetVivo Holdings, Inc. is more attractive than Pulse Biosciences, Inc..

Pulse Biosciences, Inc. has a beta of 1.776, which suggesting that the stock is 77.577% more volatile than S&P 500. In comparison PetVivo Holdings, Inc. has a beta of 0.306, suggesting its less volatile than the S&P 500 by 69.424%.

Pulse Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetVivo Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences, Inc. pays -- of its earnings as a dividend. PetVivo Holdings, Inc. pays out -- of its earnings as a dividend.

Pulse Biosciences, Inc. quarterly revenues are $86K, which are smaller than PetVivo Holdings, Inc. quarterly revenues of $286.1K. Pulse Biosciences, Inc.'s net income of -$19.4M is lower than PetVivo Holdings, Inc.'s net income of -$2.2M. Notably, Pulse Biosciences, Inc.'s price-to-earnings ratio is -- while PetVivo Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences, Inc. is 19,236.00x versus 16.79x for PetVivo Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of -22540.7% compared to Pulse Biosciences, Inc.'s net margin of 6.15%. Pulse Biosciences, Inc.'s return on equity of -73.32% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.

Pulse Biosciences, Inc. has a consensus price target of $26.00, signalling upside risk potential of 3.67%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.65 which suggests that it could grow by 3.43%. Given that Pulse Biosciences, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Pulse Biosciences, Inc. is more attractive than Zimmer Biomet Holdings, Inc..

Pulse Biosciences, Inc. has a beta of 1.776, which suggesting that the stock is 77.577% more volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.

Pulse Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 0.97% to investors and pays a quarterly dividend of $0.24 per share. Pulse Biosciences, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.04% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pulse Biosciences, Inc. quarterly revenues are $86K, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. Pulse Biosciences, Inc.'s net income of -$19.4M is lower than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, Pulse Biosciences, Inc.'s price-to-earnings ratio is -- while Zimmer Biomet Holdings, Inc.'s PE ratio is 28.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences, Inc. is 19,236.00x versus 2.40x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.